Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 5, 1996 - Issue 9
Submit an article Journal homepage
9
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Section Reviews: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthnlis: New therapeutic approaches to atopic dermatitis

John Bird Chiroscience Ltd, 283 Cambridge Science Park, Milton Road, Cambridge, CB4 4WE, UK
&
John Montana Chiroscience Ltd, 283 Cambridge Science Park, Milton Road, Cambridge, CB4 4WE, UK
Pages 1173-1180 | Published online: 03 Mar 2008

References to Primarv Literature

  • HANIF1N JM, RAJKA G: Diagnostic features of atopic dermatitis. Acta Dermatol. Venereol. (1980) 92:44–47.
  • LEUNG DYM, RHODES AR, GEHA RS, SCHNEIDER L, RING J: In: Atopic Dermatitis in 7B. Dermatology in General Medicine. Fitzpatrick TB, Gisen AZ, Wolff K, Freeburg IM, Ansten KF (Eds.), McGraw-Hill, New York (1993):1543–1564.
  • UEHARA M, IZUKURA R, SAWAI T: Blood eosinophilla in atopic dermatitis. Chi. Exp. Dermatol. (1990) 15:264–266.
  • LEUNG DYM: Immunopathology of atopic dermatitis. Springer Semin. Immunopathol. (1992) 13:427–440.
  • KAPP A: Atopic dermatitis - the skin manifestation of atopy. dim. Exp. Allergy (1995) 25:210–219.
  • SCHULTZ-LARSON F, HOLM K, I1ENNINGSEN K: Atopic dermatitis: a genetic epidemiologic study in a popula-tion-based twin sample. J. Am. Acad. Dermatol. (1986) 15:487–494.
  • HUNTER JAA, HERD RM: Recent advances in atopic dermatitis. Quart. J. Med. (1994) 87:323–327.
  • SCHUMNES E, KEIL JE: Occupational dermatoses in South Carolina: a descriptive analysis of cost variables.]. Am. Acad. Dermatol. (1983) 9:861–866.
  • HANIFIN JM: Atopic dermatitis: new therapeutic consid-erations.]. Am. Acad. Dermatol, (1991) 24:1097–1101.
  • RAJKA G, VERJANS HL: Hydrocortisone 17-butyrate (Lo-cold) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J. Int. Med. Res. (1986) 14:85.
  • FRIEDMANN PS, TAN BB, MUSABA E, STRICKLAND I: Pathogenesis and management of atopic dermatitis.Clin. Exp. Allergy (1995) 25:799-806. Review which includes discussion on pathogenesis and management of AD.
  • SCHAFER L, KRAGBALLE K: Supplementation with eve-ning primrose oil in atopic dermatitis: effects on fatty acids in neutrophils and epidermis. Lipids (1991) 26:557–560.
  • BERTH JONES J, GRAHAM-BROWN RAC: Placebo-control-led trial of essential fatty acid supplementation in atopic dermatitis. Lancet (1993) 342:377–378.
  • BERTH JONES J, GRAHAM-BROWN RAC: Evening prim-rose oil does not show promise in atopic dermatitis. Br. Med.J. (1994) 309:1437.
  • COOPER KD: Atopic dermatitis: recent trends in pathogenesis and therapy. J. Invest. Dermatol. (1994) 102:128-137. Review which includes discussion on irnmunopathology of AD.
  • SOWDEN JM, BERTH-JONES J, ROSS JS et al: Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet (1991) 338:137–140.
  • YOSHIIKE T, SINDHVANADA J, ALKAWA Y, NAKAJIMA S,OGAWA II: Topical psoralen photochemotherapy for atopic dermatitis: evaluation of two therapeutic regi-mens for in-patients and out-patients.]. Dermatol. (1991) 18:201–205.
  • COOPER KD, BAADSGAARD O, ELLIS N, DUELL E, COOR-IIERES JJ: Mechanisms of cyclosporin A inhibition of antigen presenting activity in uninvolved and lesional psoriatic epidermis. J. Invest. Dermatol. (1990) 94:649–656.
  • VAN JOOST T, KOSEL MMA, TANK B, TROOST R, PRENS EP: Cyclosporine A in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin.]. Am. Acad. Dermatol, (1992) 27:922–928.
  • TAYLOR RS, BAADSGAARD O, HEADINGTON JT et al.: Epidermal activation of autoreactive T-cells in atopic dermatitis.]. Invest. Dermatol. (1988) 90:612.
  • BAKER BS, FRY L: The immunology of psoriasis. Br.].Dermatol. (1992) 126:1–9.
  • GRIFFITHS CEM, POWLES AV, LEONARD JN et al.: Clear-ance of psoriasis with low dose cyclosporin. Br. Med.]. Clin. Res. (1986) 293:731–732.
  • HANIFIN JM, SCHNEIDER LC, LEUNG DYM et al.: Recom-binant interferon gamma therapy for atopic dermatitis. J. Am. Acad. Dermatol. (1993) 28:189–197.
  • BLOK B, TAYLOR RS, GONZALES A et al.: Peripheralbloodleukocyte subsets in atopic dermatitis: effect of gamma Interferon.]. Invest. Dermatol. (1991) 96:604.
  • BOGUNIEWICZ M, JAFFE HS, IYU A et al.: Recombinantgamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am. J. Med. (1990) 88:365–370.
  • AUDHYA T, SCHEID M P, GOLDSTEIN G: Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc. Natl. Acad. Sci. USA (1984) 81:2847–2849.
  • LEUNG DYM, HIRSH RL, SCHNEIDER L et al.: Thyrnopoie-tin therapy reduces the clinical severity of atopic der-matitis.]. Allergy Clin. Immunol. (1990) 85:927–933.
  • RANG K, COOPER KD, VANDERBANK A, HANIFIN JM: Thymopoetin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis. J. Am. Acad. Dermatol. (1983) 8:372–377.
  • ENK AH, KATZ SI: Early molecular events in the induc-tion phase of contact sensitivity. Proc . Natl. Acad. Sci. USA (1992) 89:1398–1402.
  • GEARING AJEI, BECKETT P, CHRISTODOULOU M et al.:
  • Processing of tumour necrosis factor a precursor bymetalloproteinases. Nature (1994) 370:555-557. Initial communication describing role of metalloproteinase(s) in processing of TNF-a.
  • MAILLARD JL, FAVREAU C, REBOUD-RAVAUX M: Role ofmonocyte/macrophage derived matrix metaLloprotein-ases (gelatinases) in prolonged skin inflammation. Clin. Cbim. Ada (1995) 233:61–74.
  • BACKDAHL MS, INOUE M, GIUDICE GJ, PARKS WC: 92-1Wgelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracelbilar domain of recombinant 180-id) bul-Ions pemphigoid autoantigen. J. Clin. Invest. (1994) 93:2022–2030.
  • BECKETT RP, DAVIDSON AU, DRUMMOND AH, HUXLEY P, WHITTAKER M: Recent advances in matrix metallo-proteinase inhibitor research. Drug Discovery Today (1996) 1:16-26. Review describing recent medicinal chemistry surrounding MMP inhibitors.
  • DAVIDSEN SK, SUMMERS JB: Inhibitors of TNF-a synthesis. Exp. Opin. Ther. Patents (1995) 5:1087-1100. Review of modulation of TNE-ot synthesis, including MMP inhibitors.
  • LEIFERMAN KM: Eosinophils in atopic dermatitis. J Allergy Clin. Immunol. (1994) 94:1310–1317.
  • CHAN SC, HANIFIN JM: Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.]. Lab. Clin. Med. (1993) 121:44–51.
  • TEIXEIRA MM, ROSSI AG, WILLIAMS TJ, HELLEWELL, PG: Effects of phosphodiesterase isozyme inhibitors on cutaneous inflammation in the guinea-pig. Br, J. Phar-macol. (1994) 112:332–340.
  • SEKUT L, YARNELL D, STIMPSON SA et al.: Anti-inflammatory activity of phosphodiesterase (PDE)-W inhibitors In acute and chronic models of inflammation. Clin. Exp. Immunot (1995) 100:126–132.
  • GEARING AJII, FINCHAM NJ, BIRD CR: Cytokines in skin lesions of psoriasis. Cytokine (1990) 2:68–75.
  • GROVES RW, ALLEN MIT, ROSS EL, BARKER JNWN, MAC-DONALD DM: Tumour necrosis factor alpha is pro-in-flammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br. J. Derma-to!. (1995) 132:345–352.
  • PIGUET PF, GRAU GE, HAUSER C, VASSALLI P: Tumournecrosis factor is a critical mediator in hapten induced Irritant and contact hypersensitivity reactions. J. Exp. Med. (1991) 173:673–679.
  • REINHOLD U, KUKEL S, BRZOSKA J, KREYSEL LIW: Sys-tetaic interferon gamma treatment in severe atopic dermatitis. J. Am. Acad. Derrnatol. (1993) 29:58–63.
  • MUSA1L J, MILEWSKI M, UNDAS A et al.: Interferon-gamma In the treatment of atopic dermatitis: influence on T-cell activation. Allergy (1995) 50:520–523.
  • NASERT S, MILLNER M, HERZ U et al.: Therapeutic inter-ference with interferon-gamma (IFN-gamma) and sol-uble 11-4 receptor (sIL-4R) in allergic diseases. Behring Institute Mitteilungen (1995) 96:118–130.

References to Primarv Literature

  • BAUMANN K (SANDOZ): EP569337 (1993).
  • DREYFUSS MM, LEUTWILER A, MCKENZIE AR, SCHNYDER J, MAULS H (SANDOZ): EP606044 (1994).
  • FEHR T, SANGLIER J (SANDOZ): W09506649 (1995).
  • BECKETT PR, MARTIN FM, MILLER A, WHITTAKER M (BRITISH BIOTECH LTD.): W09532944 (1995).
  • GLYCOMED, INC.: W09519965 (1995).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.